MAYWOOD, N.J.–(BUSINESS WIRE)–Sept. 23, 2004–Nymox (NASDAQ:NYMX) Has Global Patent Rights to Use of Statin Drugs for the Treatment and Prevention of Alzheimer's Disease
According to a new lead story in the September 13 2004 issue of Physician's Weekly, there is now considerable epidemiological evidence suggesting that statins, a class of widely prescribed cholesterol-lowering drugs, can reduce risk of Alzheimer's disease and possibly slow its progression. The story, "Statins: The Emerging Indications," outlines the encouraging evidence and notes that further large trials studying statins and Alzheimer's disease are now in progress.
Physician's Weekly is a weekly medical news publication widely distributed to major American hospitals and estimated to be read by over 200,000 physicians. Nymox Pharmaceutical Corporation (NASDAQ:NYMX) holds U.S. and global patent rights for the use of statin drugs for the prevention and treatment of AD. "This promising development in Alzheimer's disease treatment has caught the attention of the medical community. One of the most appealing facts about this is that some of the astronomical costs in new drug development may be avoidable," said Dr. Michael Munzar, Medical Director of Nymox.
Statins are a class of cholesterol-lowering drugs that are the biggest-selling prescription pills in pharmaceutical history with estimated 2004 global sales of up to $26 billion. Alzheimer's disease is the leading cause of dementia in the elderly, afflicting an estimated 4.5 million people in the U.S. alone. The potential for the use of statin drugs in reducing the risk of Alzheimer's disease has been featured extensively in the media such as New York Times (April 13, 2004), Fortune magazine (August 9, 2004), Newsweek magazine (Jan 19, 2004), The Los Angeles Times (June 22, 2003), and The Wall Street Journal (April 17 and 18, 2002).
Numerous scientific and clinical studies have explored the potential benefits of statin drugs to prevent or treat AD. Studies have shown up to 70% reduction in AD incidence in individuals who use statin drugs. In addition of recent studies presented at major medical conferences, published peer-reviewed studies include, for example, International Journal of Geriatric Psychiatry 2004;19:327-32; Neuroepidemiology 2004; 23:94-8; Neuron 2004; 41:7-10; Arch Neurol 2000; 57:1439-1443; Lancet 2000; 356:1627-1631; Arch Neurol 2002; 59:223-227; J Gerontol Biol Sci Med Sci 2002;57:M414-M418; and J Am Geriatr Soc 2002;50:1852-1856. More information about Nymox is available at www.nymox.com, email: email@example.com, or 800-936-9669.
This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.